Related references
Note: Only part of the references are listed.The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
David Davidson et al.
INVESTIGATIONAL NEW DRUGS (2013)
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
C. Leonetti et al.
CURRENT CANCER DRUG TARGETS (2012)
DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets
M. Alagoz et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
Anand G. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells
Giovanna D'Onofrio et al.
BIOCHEMICAL PHARMACOLOGY (2011)
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Common fragile sites in colon cancer cell lines: Role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1
Patrizia Vernole et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2011)
Treatment of Metastatic Colorectal Cancer
Janine M. Davies et al.
SEMINARS IN ONCOLOGY (2011)
Therapeutic Targeting of the DNA Mismatch Repair Pathway
Sarah A. Martin et al.
CLINICAL CANCER RESEARCH (2010)
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
L. Tentori et al.
CURRENT CANCER DRUG TARGETS (2010)
Genetic Instability Influences Drug Response in Cancer Cells
G. Damia et al.
CURRENT DRUG TARGETS (2010)
Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
Rachel A. Daniel et al.
CLINICAL CANCER RESEARCH (2009)
Recent Approaches to Improve the Antitumor Efficacy of Temozolomide
Lucio Tentori et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Platinum resistance: The role of DNA repair pathways
Lainie P. Martin et al.
CLINICAL CANCER RESEARCH (2008)
Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks
Haruyuki Takemura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma
Lucio Tentori et al.
FASEB JOURNAL (2006)
Poly(ADP-ribose):: novel functions for an old molecule
Valerie Schreiber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
ATR kinase activation mediated by MutSα and MutLα in response to cytotoxic O6-methylguanine adducts
Ken-Ichi Yoshioka et al.
MOLECULAR CELL (2006)
The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks
LM Smith et al.
CLINICAL CANCER RESEARCH (2005)
Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2
AW Adamson et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing
M Malanga et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361
CR Calabrese et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR-Chk1 pathway
K Yamane et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells
E Papouli et al.
CANCER RESEARCH (2004)
Cellular effects of CPT-11 on colon carcinoma cells:: Dependence on p53 and hMLH1 status
R Magrini et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Resistance to topoisomerase poisons due to loss of DNA mismatch repair
A Fedier et al.
INTERNATIONAL JOURNAL OF CANCER (2001)